Sunday, November 30, 2025

⚡ Tesla + NVIDIA rep to Congress: It’s time

Every investor needs to see this ASAP ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

A message from Brownstone Research   

Dear Reader,

Why isn't this document on every front page in the country?

Image

On March 26...

Just one week before Trump's Liberation Day…

This document was presented to congress on Capitol Hill.

It was written by a task force representing some of America's most powerful companies.

Most people have never heard of this elite group…

But they speak for more than 1,300 organizations…

Including multi-billion-dollar tech giants like Tesla, NVIDIA, and Intel.

As far as I can see, this document could be a major reason Trump was willing to pull the trigger on his Liberation Day tariffs…

But more importantly, I believe this document spells out the next move in the trade war…

And anyone who knows what's inside could prime their portfolios for stratospheric gains.

That's why I've lifted the lid on what's hidden in this jaw-dropping document…

Because chances are you'll never hear it in the mainstream media.

Click here now to see what the document reveals.

Regards,

Jeff Brown
Founder & CEO, Brownstone Research





This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



🚨 The $1.9 trillion industry AI is about to demolish

this could be your chance at 1,000%+ gains. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from InvestorPlace Media

Dear Reader,

I'm here in Silicon Valley right now...

Just down the street from an AI company most Americans have never heard of.

But my guess is, you'll be using their service very soon.

This company has figured out how to use AI to disrupt a massive $1.9 trillion industry that hasn't changed in decades.

And here's the crazy part:

It trades for just under $8 today.

I was once voted America's #1 Stock Picker, beating out nearly 15,000 Wall Street analysts…

My readers have had the chance to see gains like 15X on Shopify... and 83X on AMD…

Now I'm giving away my next pick — completely FREE.

Click here to get the name and ticker symbol in just 5 minutes.

No credit card or email address required.

Just the company name, ticker symbol and full details on why this could be your chance at 1,000%+ gains.

Regards,

Luke Lango
Senior Tech Analyst, InvestorPlace

This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201.





This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



🚨 Breaking: Trump’s Secret Plan to Kill the IRS ☠️

Want to be first in line for up to $21,307? Here's your chance. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from Angel Publishing   

Something historic is unfolding in Washington — and it could change your financial future FOREVER.

Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-changing system designed to replace income taxes and send direct payouts to everyday Americans.

More than $1 TRILLION is expected to be distributed... and YOU could be eligible to claim a massive check.

Here's how to be first in line to collect up to $21,307 — BEFORE the first checks to the public go out.

But you must act fast…

Click here to claim your stake before it's too late. 

To your wealth,

Brian Hicks
Founder and President, Angel Investment Research





This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



[December 1st] ⏳ Last Chance to Claim Your Stake in Elon’s Private Company, xAI

A rare opportunity to invest in Elon's private AI company ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

A message from Brownstone Research   

Dear Reader,

Even though xAI is a private company…

Tech legend and angel investor Jeff Brown found a way for everyday folks like you…

To "partner" with Elon on what he believes will be the biggest AI project of the century.

Click here to see how you could take a stake in Elon's private company…

Without having connections in Silicon Valley…

Without having to be an accredited investor…

And without having to be rich.

In fact, you can get started with as little as $500.

And it could be as easy as buying any other stock.

Click here now because it's critical that you act before December 1st.

Regards,

Lindsey Hough
Managing Director, Brownstone Research





This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



1 Must-Buy Stock For Monday [Dec 1st] 🗓️

Previous picks gained +149%, +190%, +536%—see the next potential winner. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from StocksToTrade   

Want to start next week off with a big win?

 

Our new algorithm may have just uncovered a new dirt-cheap stock with a great chance of moving +100% or more this Monday.

 

...One ticker…

 

…One trade... 

 

…One MONSTER move…

 

All you have to do is make this one trade on Monday.

 

While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day.

 

And we think this new pick could be just as big.

 

But if we're right, it may move FAST…

 

So get the details now.

 

-Tim Sykes

 

 

1. Results are not typical. I teach methods that have made other traders money, but that does not guarantee you will make any money. Success in trading requires hard work and dedication. Past performance does not indicate future results. All trading carries risks.




Today's editorial pick for you

3 of the Best Residential REITs to Buy for 2026


Posted On Nov 25, 2025 by Chris Markoch

The case for residential REITs is becoming hard to ignore. Homeownership may still be the American dream, but data shows that America is still a renter's nation.

And recent data indicates that’s not likely to change anytime soon. Renter households continue to grow faster than homeowner households. According to Barron's:

"With house prices still high, mortgage rates stuck just under 7%, and plenty of economic uncertainty, consumers are once again seeing the virtues of renting. Over a third of respondents, 35%, told Fannie Mae in April that they would rent instead of buy if they had to move, the highest share since October and more than the long-term average of three in 10."

Residential REITs aren’t going to beat the growth opportunities that growth investors can get from stocks that are part of the artificial intelligence (AI) trade. However, they can be a solid choice for income-oriented investors, particularly at at a time when interest rates are coming down, which makes short-term Treasury bills less appealing.

In fact, REITs are required to pay a healthy percentage of their earnings to shareholders. That means the certainty of regular dividends. If you think that real estate investment trusts (REITs) may be right for you, here are three names to consider.

Residential REITS #1: Mid-America Apartment Communities

With a yield of just over 4.54%, Mid-America Apartment Communities (NYSE: MAA) is an attractive, oversold opportunity.  The REIT focuses on apartment communities in the Southeast, Southwest and Mid-Atlantic regions of the U.S.

MAA stock is down 13.5% in 2025. However, the stock has risen approximately 5% since its earnings report on October 30. At that time, the company reported strong operating results with 95.6% physical occupancy, a 4.5% increase in renewals, and net delinquency at just 0.3%, indicating resilient demand and collections.

MAA also paid a dividend of $1.515 per share on October 31, July 31, April 30, and January 31. Its next dividend payment should come at the end of January 2026.

Residential REITs #2: Camden Property Trust

With a yield of about 4%, Camden Property Trust (NYSE: CPT) is one of the largest publicly traded multifamily companies in the United States. The company is primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. It also owns and operates 177 properties.

CPT stock is down about 9.8% in 2025. However, it’s up about 7% since October 31. Part of those gains is due to the company’s strong earnings report.

In its most recent earnings report, the company's funds from operations of $1.67 was in-line. Revenue of $395.68 million, up 2.2% year over year, missed by $2.86 million.

Camden Propery Trust has a high-yield dividend of 4.02%. It pays out $4.20 per share on an annual basis. The most recent dividend payment of $1.05 per share came on October 17, 2025.

Residential REITs #3: AvalonBay Communities

With a yield of 3.87%, AvalonBay Communities (NYSE: AVB) invests in apartments. It just declared a dividend of $1.75 per share, which will be paid on January 15 to shareholders of record as of December 31.

AVB stock is down about 18% in 2025, but has climbed about 3% since November 1. That corresponds to its earnings report on October 30. At that time, the company lowered its full-year core FFO guidance by $0.14 to $11.25, reflecting weaker same-store NOI and implied year-over-year earnings growth of about 2.2%.

Most recently, analysts at Barclays, Scotiabank, and Morgan Stanley raised their price targets on the AVB stock. Morgan Stanley raised its price target to $228 with an equal-weight rating on the stock. Scotibank raised its price target from $241 to $251. 




This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com




Today's Bonus Content: The biggest threat to American life and wealth right now

⏳ This Weekend Only: The Robotics Opportunity Too Big to Ignore – Just $19

A Trump Order Could Send This $7 Stock Soaring ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from Weiss Ratings   

Dear Reader,

Something big is brewing in Washington.

According to my research, an executive order from President Trump could be just weeks away.

And it holds the potential to trigger one of the most explosive tech booms in US history.

At the center of it all? Robots.

Not the kind that clean your house or pour you coffee.

But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.

You see, there's just one final obstacle.

One executive order and the floodgates open.

And it could happen soon ….

The best part?

This $7 stock — which has already partnered with Nvidia, FedEx, Toyota, and Volvo — is in the perfect position to capitalize.

But it might not stay "under-the-radar" for very long.

The time to act is now, because for a limited time …

This Cyber weekend only …

We're giving you insider access to ALL of Weiss Ratings' Disruptors and Dominators benefits…

Full of executive-quality research on the exciting world of tech investing … For just $19.

That's a savings of 85%!

This rare opportunity won't last long, so click here now to see how you can benefit before it's gone.

Best,

Michael Robinson
Michael Robinson
Weiss Ratings

 





This is a PAID ADVERTISEMENT provided to the subscribers of Daily Options Signals Free Newsletter. Although we have sent you this email, Daily Options Signals and StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us. If you no longer wish to receive email from DailyOptionsSignals.com, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



⏳ 24 Hours Left: Unlock Trump's $21T Dollar Shift?

A $21 trillion financial revolution ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from Brownstone Research   

Editor's Note: After correctly predicting the rise of Bitcoin, Nvidia, and Tesla's self-driving cars, tech legend Jeff Brown is now predicting the rise of what he calls "Trump's new dollar," which is a better, more technologically advanced version of the U.S. dollar. Click here for the details or read more below.


Dear Reader,

If you have any money in U.S. dollars…

You need to click here and prepare for what could be the biggest change to our financial system in 54 years.

You see, President Trump just signed a new law…

Setting the legal framework for a better, more technologically advanced version of the U.S. dollar.

And no, I'm not talking about gold, central bank digital currencies, Bitcoin, or anything you might have heard before.

Instead, it's a new currency that has been called "the future of money."

President Trump himself called it a "big innovation"...

And said that this new dollar represents "American brilliance at its best."

I believe what I'm calling "Trump's NEW dollar" is going to make a lot of people rich in America.

Congressional hearings are already projecting growth of 1,900% for this new type of currency.

As you're about to see…

That could be a very conservative estimate.

The famous tech-centric hedge fund ARK Invest recently put out a note to its clients saying…

"We believe [Trump's new dollar] is poised for exponential growth."

That's why you need to act fast here…

With this exponential growth…

By the time most people realize what's happening with the U.S. dollar…

It will be too late…

And the chance to profit big might be gone forever.

Click here to get the details before it's too late.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research





This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



ChatGPT Is Three. Don’t Crack the Bubbly Just Yet

To get John Authers' newsletter delivered directly to your inbox, sign up here. Happy third birthday to ChatGPT! Nno nneed to guess which st
View in browser
Bloomberg

To get John Authers' newsletter delivered directly to your inbox, sign up here.

Today's Points:

ChatGPThree Years Old

It's been three years since ChatGPT launched itself on to an unsuspecting world. Much like the opening of the World Wide Web to the public in 1993, it took a technology that had been growing for years and suddenly made it accessible to a broader public. It's had a similarly galvanic effect. Nov. 30, 2022, increasingly looms as a date when things changed.

Much has been written about this, of course. Sticking to the market impact, the ChatGPT world has been one dominated by a few very big winners to date. The S&P 500 stock that has gained most in that time is, of course, Nvidia Corp. A rough ride in the last few days has brought the three-year gain in the share price a little below 1,000%. Beyond that, it's fascinating how concentrated the returns have been:

It's not unusual for some company somewhere to grow this much in three years. It's unprecedented for a firm that is already established among the world's largest to do so. That can be attributed both to the belief that AI will be transformative, and that Nvidia will be able to maintain a quasi-monopolistic position; with so much now running on these propositions, it's not surprising that both are coming in for re-examination. 

What is surprising is that generative AI hasn't yet altered the global order beyond showering capital on a few very large US companies that obviously stand to benefit. Using Bloomberg's index of the 500 largest US stocks excluding the Magnificent Seven tech groups, and comparing it with FTSE's index of all the developed and emerging markets outside the US, the two look more or less identical, and neither really springs into life until a year after the ChatGPT launch:

The amounts being spent on Nvidia chips are truly phenomenal, as Points of Return has documented, while the capital expenditures in the pipeline are big enough to shift forecasts for the entire economy. But as far as financial markets are concerned, this is still at base a story to an explosion in valuations for a select few companies viewed as likely winners.

This chart compares the price/earnings ratios of the S&P 500 cap-weighted index (of which the Magnificent Seven now account for more than a third), and the equal-weighted index, in which each company accounts for 0.2%. Normally, the two move tightly together. Both were on the low side when ChatGPT came out, following the brief but savage bear market that accompanied post-pandemic rate hikes to rein in inflation. Thus, some of the great performance since then is due to starting cheap, rather than to the revolutionary new technology.

But the equal-weight P/E really hasn't increased that much. What changed almost instantly was the divergence between the equal-weight and cap-weight indexes. The valuation of the average US stock is high-ish but unremarkable. The overall index, giving full weight to the Magnificents, looks expensive: 

Where does all this leave us? The debate over whether this is a bubble gets a little arid, and depends too much on exactly how you define "bubble." We all have the opportunity to experiment with ChatGPT and other similar apps that have followed it, all of which have improved greatly in the last three years. There's obviously something exciting there, and it's in the nature of markets to try to be ahead of the curve. When you buy a stock you are taking on its future earnings stream, not what's in the past.

All that said, the stock market is telling us that so far this technology hasn't changed much of anything, beyond sparking massive growth in a few companies, which is based mostly on hopes for the future. It may not be through the bursting of a bubble, but somehow or other the lines on these charts are going to join each other again before ChatGPT has many more birthdays, either in losses for the Magnificents or gains for everyone else. Either way, it makes sense to take a deep breath and find ways to overweight everyone else, not US Big Tech hyperscalers. 

The Magic Pill

With Thanksgiving over, thoughts turn to the issue of how to lose a few pounds. And obesity drugs have suddenly made that much more attainable, while earning big dollars for their manufacturers. It's no coincidence that the stock that has contributed most to the rise of the S&P 500 in the three years of ChatGPT — and that wasn't in the Magnificent Seven — was Eli Lilly & Co., maker of Ozempic and Mounjaro. It's gained 202% in that time, which is more than Apple Inc., Microsoft Corp., Amazon.com Inc. or Tesla Inc. 

But for all the talk about the enormous market for these drugs, which seems even bigger as the country stirs after a few days of enforced gluttony, the issue of cost won't go away. That hurdle just got lower with Washington's recently announced discounts on Novo Nordisk A/S's blockbuster drugs Ozempic and Wegovy for Medicare patients, the federal health insurance program for the elderly. The 71% discount may delight patients and voters alike, but drugmakers will feel the pinch unless volume growth can overcome the margin squeeze. 

Bloomberg Intelligence estimates that Eli Lilly and Novo Nordisk's GLP-1 obesity drug sales could fall by at least $2 billion in 2026 to $26.4 billion. Medicare's coverage, set to begin next spring, should extend eligibility to at least 10 million potential patients, which BI analysts Michael Shah and Bethan Swift argue won't be enough to offset the price cuts. The discount has barely swayed investor sentiment, with Novo Nordisk still seen as a big loser, if the stock's reaction since the announcement is anything to go by:

The Danish company has endured a rough spell. Its growth prospects are heavily dependent on Ozempic (for diabetes) and Wegovy (for obesity), which both face headwinds. Shah argues these have fueled multiple guidance cuts, creating uncertainty for 2026:

The company is now trading at a forward P/E that's broadly in line with large pharma peers. Yet, despite this significant derating, sentiment about the stock is unlikely to improve until we get greater visibility around compounded GLP-1s (hurting Wegovy) and the measures in place to tackle them, plus evidence of improved commercial execution.

Despite both Lilly and Novo Nordisk being forced to swallow Washington's price cuts, it's Lilly's third-quarter earnings strength and its raised outlook that have investors leaning in. Expectations around the company's much-awaited weight-loss pill have helped propel it to an all-time high, making it the first health-care company to cross the $1 trillion market-cap threshold:

Ahead of a US Food and Drug Administration decision on whether to approve Lilly's oral obesity medication expected in early 2026, the firm has bulked up its supply. The elusive weight-loss pill remains the central catalyst in a market expected to reach $95 billion by 2030. Lilly's stock, up nearly 40% this year after a 32% surge in 2024, suggests investors are doubling down on the view that it will stay among the winners in the race to treat the obesity epidemic. It's running far ahead of the sector as a whole — this is how these exchange-traded funds tracking products and services related to cardiovascular and metabolic diseases, as defined by the Centers for Disease Control, have fared year-to-date:

The TEMA Heart & Health ETF, launched a year ago, is hovering around record levels. Is the optimism justified? Judging from third-quarter health-care earnings, which produced more positive surprises than any other sector, it appears so. Demand for high-cost specialty drugs, including cancer treatments, helped power strong results at distributors such as McKesson Corp., Cencora Inc., and Cardinal Health Inc.:

Their performance might also conceivably stem from using AI to improve the efficiency of pharmaceutical R&D. The iShares Biotechnology ETF has surged for six straight months, its longest winning streak since 2012. It's currently on track to eclipse the all-time peak it achieved at the height of optimism for Covid vaccines:

AI is already being put to work in biotech to deal with high failure rates, steep costs, and long development timelines, according to PitchBook. And so far, it's paying off. Biotechs that have baked AI into their model from the start now command nearly a 100% valuation premium to their non-AI peers:

While AI tools for experimental design and clinical-trial optimization will likely continue to be integrated into drug development, the success of AI-discovered assets will be the most significant benchmark for the technology and will have the greatest impact on the biopharma business model.

A lot, of course, is riding on faith in AI as the spark for a productivity revolution. And the experience of the companies that pioneered Covid vaccines shows that it's best not to take anything for granted: in the three years of ChatGPT, Pfizer Inc. is down 38% and Moderna Inc. has lost 85% — they have the second- and fourth-largest losses of market cap in the entire S&P 500. But for now, confidence in weight-loss pills and the curative properties of AI are enough to draw the sting from the Washington Medicare deal. 

-- Richard Abbey

Survival Tips

Tom Stoppard has left us at 88. He has been a part of the literary canon for as long as I can recall, and he doesn't deserve to be remembered for Shakespeare in Love, which I think is overrated — Upstart Crow basically made the same joke much more funnily. So instead, check out his great Cold War television play Professional Foul, or his laugh-aloud early comedy The Real Inspector Hound (now a staple of high school and college drama societies). It's a pastiche on Agatha Christie that has a lot in common with the Knives Out movies that we all enjoy. Or there's his early Rosencrantz and Guildenstern Are Dead, which has always been a fantastically useful reference on finance and probability theory. It starts with the heroes tossing a coin, calling heads 99 times in a row, only for it to come up tails every time. Discuss. Have a great week everyone. 

More From Bloomberg Opinion:

  • Capitalism's Latest Critic Ignores Its Secret Sauce: Adrian Wooldridge
  • Ray Dalio's Hedge Fund Bug Looks More Like a Feature: Chris Hughes
  • OPEC's Numbers Are an Exercise in Artistic Deception: Javier Blas

Want more Bloomberg Opinion? OPIN. Or you can subscribe to our daily newsletter.

Like Bloomberg's Points of Return? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters like Markets Daily or Odd Lots.

Like getting this newsletter? Subscribe to Bloomberg.com for unlimited access to trusted, data-driven journalism and subscriber-only insights.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Points of Return newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices